Senator Warned U.S. Lags Behind China in Biomanufacturing
Biotech advancements carry dual-use risks for national security while creating dependency on Chinese supply chains.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Should the U.S. prioritize biomanufacturing self-sufficiency over maintaining collaborative research ties with foreign nations?
Senator Todd Young stated that the U.S. currently lags behind China in biomanufacturing capabilities during an Axios event on September 23, 2026. Panelists highlighted how the biopharma industry remains dependent on China for essential drugs and global supply chains.
Why it matters
The intersection of biotech development and national security necessitates balancing research collaboration with the protection of warfighters. While AI tools like those used by Genentech accelerate drug discovery, the reliance on external supply chains presents persistent systemic vulnerabilities.
Genentech has demonstrated the capacity to condense early-stage research timelines from years to months using artificial intelligence models. This performance gain marks a significant departure from conventional drug development cycles.
The players
Todd Young
A United States Senator who has highlighted the national security implications of the U.S. reliance on Chinese biotech infrastructure.
Genentech
A biotechnology corporation focused on genetic research and drug development that integrates AI to accelerate its R&D pipeline.
April McClain Delaney
A member of the U.S. House of Representatives who identified the scale of Chinese government investment in the biotechnology sector.
Maria Ghazal
A policy expert who warned that overly restrictive collaboration policies could hinder access to drug innovation for U.S. patients.
The details
Genentech utilizes AI algorithms to simulate and analyze molecular interactions, effectively shortening the trial-and-error phases of drug discovery. The industry simultaneously navigates the dual-use nature of biotech, where innovations intended for public health applications also possess potential risks to national security and defense infrastructure.
Timeline
September 23, 2026: Senator Todd Young and panelists discussed the state of U.S. biomanufacturing at an Axios event.
The Tech Race
The U.S. government currently manages an AI hotline with China to mitigate emerging risks, and Senator Todd Young has suggested expanding this framework to incorporate biological threats. The proposal to include biological threats updates the scope of the existing communication protocol to address evolving biotech security risks.
The potential shift in supply chain standards may influence the availability and cost of pharmaceuticals as the U.S. seeks to reduce dependence on foreign manufacturers. Future federal policies will determine whether these changes prioritize domestic production or international collaboration.
The takeaway
The trajectory of the U.S. biotech sector depends on balancing rapid AI-driven research against the vulnerabilities of the current global supply chain. Stakeholders should monitor upcoming federal discussions regarding potential export controls and new biosecurity standards for the industry.
Further reading
Explore the current state of industry research and national policy in our Biotech section.
Source note: This article includes information reported by Axios.
Live Poll
Should the U.S. prioritize biomanufacturing self-sufficiency over maintaining collaborative research ties with foreign nations?
